Table 4.
Author/year | Patient no (P:NP) | Methods | Methylation threshold definition | Statistical analysis | Result |
Boerwinkel et al 201443 | 44 (48:10) |
Methylight methylation-specific PCR | Previously published cut-off values applied to raw MSP data to calculate frequency of hypermethylation. RUNX3 cut-off=0.02 | Mann-Whitney test | Raw MSP values compared but no numerical value offered P versus NP not significantly differentially methylated |
Jin et al 200941 | 195* (50:145) |
Methylation-specific PCR | NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR | Student’s t test and chi-squared test AUROC |
Hypermethylated in P NMV 0.104:0.063 AUROC=0.671 (0.586, 0.756) 90% sensitivity 90% specificity P=0.0002 |
Sato et al 200840 | 62 (28:34) |
Methylation-specific PCR | NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR | LDA, LOOCV, AUROC | Hypermethylated in P AUROC increment when added to segment length, histology and global methylation index=0.0216 90% sensitivity 90% specificity P=0.016 |
Schulmann et al 200539 | 53 (8:45) |
Methylation-specific PCR | NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR | Cox proportional HRs | Hypermethylated in P OR=1.80 P=0.0267 |
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
AUROC, area under receiver operating characteristic; LDA, linear discriminant analysis; LOOCV, leave-one-out cross-validation; MSP, methylation specific PCR; NMV, normalised methylation value; NP, non-progressing patients; P, progressing patients.